Sunesis Pharmaceuticals to Report 2005 Financial Results on March 24, 2006

SOUTH SAN FRANCISCO, Calif., March 17  /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics, today announced that Sunesis senior management will hold an investor conference call to discuss 2005 fourth-quarter and year-end financial results on Friday, March 24, 2006 at 7:30 a.m. PST/10:30 a.m. EST.

Individual and institutional investors can access the call via 800-811-0667 (domestic) or 913-981-4901 (international).  To access the live audio broadcast or the subsequent archived recording, visit the "Investors and Media -- Calendar of Events" section of the Sunesis website at http://www.sunesis.com/ .  Please log on to Sunesis' website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases.  Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics.  Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies.  For further information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com/ .

Safe Harbor Statement

This press release contains forward-looking statements that involve substantial risks and uncertainties.  Sunesis may not actually achieve the plans, intentions or expectations contained in such forward-looking statements.  Actual results or events could differ materially from the plans, intentions and expectations contained in such forward-looking statements. Sunesis does not assume any obligation to update any such forward-looking statements. 

DATASOURCE: Sunesis Pharmaceuticals, Inc.



CONTACT:  investors, Eric Bjerkholt, CFO of Sunesis Pharmaceuticals,

Inc., [phone]; or media, Karen L. Bergman, [phone], or

Michelle Corral, [phone], both of BCC Partners, for Sunesis

Pharmaceuticals, Inc.



Web site:  http://www.sunesis.com/ 

Copyright